Welcome to our dedicated page for Quantum-Si Incorporated news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si Incorporated stock.
Quantum-Si Incorporated (symbol: QSI) is revolutionizing the field of proteomics with cutting-edge technologies. The company has developed a unique semiconductor chip that enables single-molecule, next-generation protein sequencing and genomics, going beyond traditional DNA sequencing. This innovation is set to digitize proteomic research, significantly advancing drug discovery and diagnostics.
Founded by successful entrepreneurs and fully funded to focus on groundbreaking science, Quantum-Si fosters an environment where highly committed individuals are encouraged to solve tough problems and create impactful technologies. The company is headquartered in Guilford, Connecticut, and continues to attract bright minds dedicated to transforming healthcare.
Quantum-Si's core products include a suite of technologies that leverage their proprietary semiconductor chip for high-precision protein analysis. These products are designed to provide deeper insights into the proteome, which is essential for understanding diseases, developing new therapies, and personalizing medicine.
Recent achievements highlight Quantum-Si's commitment to innovation and excellence. The company has formed strategic partnerships with leading research institutions and pharmaceutical companies to accelerate the adoption of its technologies. Additionally, Quantum-Si continues to invest in research and development to enhance its product offerings and expand its market reach.
Financially, Quantum-Si is backed by substantial funding from its founders, allowing the company to prioritize innovation and market entry without the immediate pressures of profitability. This financial stability ensures that the company can focus on long-term goals and sustainable growth.
For those interested in joining a dynamic and innovative team, Quantum-Si offers a range of career opportunities. Visit their job postings at 4Catalyzer to learn more about current openings.
Empower discovery. Empower health. Empower you.
Quantum-Si (QSI) and several researchers will present new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting from February 23-26th. The presentations will include three scientific posters showcasing Next-Generation Protein Sequencing (NGPS™) innovations:
1. Dr. Meredith Carpenter from Quantum-Si will present how NGPS detects protein-level changes and post-translational modifications
2. Dr. Gloria Sheynkman from University of Virginia will demonstrate the integration of long-read RNA sequencing with the Platinum™ benchtop instrument for single-molecule peptide sequencing
3. Dr. Winston Timp from Johns Hopkins University will showcase how NGPS enables direct peptide sequencing to identify protein partners, offering a cost-effective alternative to legacy technologies
Quantum-Si (Nasdaq: QSI) announces its participation at the US Human Proteome Organization's 2025 conference in Philadelphia, featuring advances in Next-Generation Protein Sequencing™ (NGPS™). The company is sponsoring a panel discussion titled 'Breaking Boundaries: How Next-Generation Protein Sequencing™ is Shaping the Future of Proteomics' on February 25.
The event will showcase research using Quantum-Si's Platinum® Pro benchtop instrument, including new protein barcoding and library preparation solutions. Notable researchers from Washington University, University of Illinois Chicago, and University of Michigan will discuss NGPS's impact on proteomics.
Four scientific posters will be presented, covering: tropomyosin isoform differentiation, reduced protein input requirements, peptide variant mixture measurement, and protein barcoding for multiplexed analysis.
Quantum-Si (QSI) has announced it will release its fourth quarter and full year 2024 financial results on Monday, March 3, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day, featuring President and CEO Jeff Hawkins and CFO Jeff Keyes, who will discuss the financial results and provide a business update.
Interested participants can join via webcast through the Investors section of Quantum-Si's website under Events and Presentations, or register for a personalized dial-in number. A replay of the event will be available afterward.
Quantum-Si (Nasdaq: QSI) announces a new preprint from Northwestern University researchers demonstrating the combined use of their Next-Generation Protein Sequencing™ (NGPS™) technology and Individual Ion Mass Spectrometry (I2MS) for analyzing interleukin-6 (IL-6), a key immune regulator and therapeutic target.
The study reveals that NGPS provided single amino acid resolution for IL-6 peptide fragments critical to receptor binding and function, while I2MS enabled intact proteoform detection and localized modifications, including glycosylation. The combination of these technologies offers comprehensive coverage of IL-6's structural and functional diversity, potentially advancing therapeutic research in complex diseases like cancer and autoimmune disorders.
Quantum-Si (Nasdaq: QSI) has announced the formation of its Scientific Advisory Board (SAB) to guide its next-generation proteomic technologies development. Dr. Gloria M. Sheynkman, Assistant Professor at the University of Virginia, has been appointed as Chair of the SAB. The board includes distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering.
Key board members include Dr. Benjamin A. Garcia from Washington University School of Medicine, Dr. Bradley L. Pentelute from MIT, and Dr. Denis Zaccarin, former Senior VP of R&D at PacBio. The SAB will focus on shaping scientific strategy, identifying emerging trends, and strengthening scientific community engagement. They will also support Quantum-Si in prioritizing applications and fostering collaborations for their next-generation protein sequencing (NGPS) technology and Proteus™ platform.
Quantum-Si (Nasdaq: QSI) has announced a strategic partnership with IDEX Health & Science for the development and manufacturing of the optics module for their Proteus™ proteomics platform. IDEX Health & Science, a global leader in life science optics, fluidics, and microfluidics, will leverage their expertise through their Melles Griot and Semrock product lines to support the design, development, and manufacturing of the Proteus optics module.
The partnership aims to utilize IDEX's experience in complex optical systems for life sciences instrumentation, with QSI targeting to bring the novel platform to market by the second half of 2026. The collaboration is expected to accelerate scientific advancements and mitigate risks associated with timelines and product launches, ultimately contributing to breakthroughs in drug discovery, diagnostics, and human health.
Quantum-Si (Nasdaq: QSI) announced its participation in the Festival of Genomics UK, scheduled for January 29-30, 2025, at ExCeL London. Dr. Richard Broadhead will present on Next-Generation Protein Sequencing™ and its impact on proteomics research, featuring the company's Platinum® Pro platform.
The presentation will showcase three key advancements:
- A new Protein Barcoding Kit for multiplexed peptide barcoding
- Library Prep Kit V2 for streamlined sample preparation
- Integrated software for unified data generation and analysis
The technology enables single-molecule protein sequencing with high precision in protein identification and proteoform characterization, particularly in distinguishing proteoforms from amino acid changes, alternative splicing, and post-translational modifications. This capability enhances the integration of proteomic data with genomic and transcriptomic research.
Quantum-Si (QSI) has announced the granting of 44,893 restricted stock units (RSUs) to new employees through its 2023 Inducement Equity Incentive Plan. The grants, approved by the Compensation Committee of QSI's Board of Directors, serve as inducement material for new hires in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will follow a vesting schedule where 25% will vest on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with the company. These equity awards are exclusively granted to individuals who were not previously QSI employees, as part of their employment compensation package.
Quantum-Si (Nasdaq: QSI) launches Platinum® Pro, a new benchtop sequencer aimed at revolutionizing protein analysis in proteomics research. The system is now available for ordering and features a comprehensive, integrated workflow designed to simplify complex protein sequencing.
Key innovations include an enlarged touchscreen with an elegant user interface, flexible data analysis options (local and cloud-based), and a Pro Mode for custom application development through a Technology Access Program. The product is intended to democratize access to proteomics, providing tools for diverse applications from proteoform analysis to protein barcoding.
CEO Jeff Hawkins emphasizes Platinum Pro's role in making proteomics more accessible, while Chief Commercial Officer Todd Bennett highlights a new partnership with Avantor, which will expand the product's availability in the U.S. and Canada. The system is expected to drive new opportunities for breakthrough discoveries and will begin shipping in the first quarter.
For more information or to place an order, visit Quantum-Si's website.
Quantum-Si (Nasdaq: QSI) has released a new preprint demonstrating the integration of their benchtop Platinum® instrument with protein barcoding technology. The study showcases a novel workflow that enhances multiplexed protein analysis with improved sensitivity and accessibility compared to traditional methods like mass spectrometry.
The research validated eight peptide barcodes designed for minimal detection bias and maximum sensitivity, featuring a streamlined workflow that reduces sample input requirements and hands-on time to under one hour. The system demonstrated a ten-fold dynamic range for detecting low-abundance proteins.
The combination of QSI's Platinum® Pro instrument with their protein Barcoding Kit offers advantages over DNA barcodes by providing direct quantitative readout of protein expression and localization. This advancement has potential applications in protein engineering, targeted drug delivery, and nucleic acid therapy development.
FAQ
What is the current stock price of Quantum-Si Incorporated (QSI)?
What is the market cap of Quantum-Si Incorporated (QSI)?
What does Quantum-Si Incorporated do?
What is the significance of Quantum-Si's semiconductor chip?
Where is Quantum-Si headquartered?
Who funds Quantum-Si?
What are Quantum-Si's core products?
What recent achievements has Quantum-Si made?
What opportunities are available at Quantum-Si?
How does Quantum-Si contribute to healthcare?
What is the financial condition of Quantum-Si?
How can I stay updated with the latest news about Quantum-Si?
